![John Geddes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Geddes
Corporate Officer/Principal bei CARDIOL THERAPEUTICS INC.
Aktive Positionen von John Geddes
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Corporate Officer/Principal | 01.01.2022 | - |
Karriereverlauf von John Geddes
Ehemalige bekannte Positionen von John Geddes
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Novo Nordisk Canada, Inc.
![]() Novo Nordisk Canada, Inc. Pharmaceuticals: MajorHealth Technology Novo Nordisk Canada, Inc. provides healthcare services. The firm specializes in the areas of coagulation disorders, growth disorders and hormone replacement therapy. The company was founded in 1993 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - | - |
Vasogen, Inc.
![]() Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Corporate Officer/Principal | - | - |
LUMINEX CORPORATION | Corporate Officer/Principal | - | - |
Ausbildung von John Geddes
Richard Ivey School of Business | Masters Business Admin |
Queen's University | Undergraduate Degree |
Statistik
International
Kanada | 5 |
Vereinigte Staaten | 2 |
Hong Kong | 2 |
Operativ
Corporate Officer/Principal | 4 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Luminex Corp.
![]() Luminex Corp. Medical SpecialtiesHealth Technology Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The firm's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The company was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX. | Health Technology |
Novo Nordisk Canada, Inc.
![]() Novo Nordisk Canada, Inc. Pharmaceuticals: MajorHealth Technology Novo Nordisk Canada, Inc. provides healthcare services. The firm specializes in the areas of coagulation disorders, growth disorders and hormone replacement therapy. The company was founded in 1993 and is headquartered in Mississauga, Canada. | Health Technology |
Vasogen, Inc.
![]() Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Börse
- Insiders
- John Geddes
- Erfahrung